Viral vector manufacturing software.

Viral vector manufacturing is a convergence problem. Plasmids or a producer-cell system, a cell bank, media and transfection materials, culture, harvests, purification pools and several assay systems all feed one vector lot, and every dose must stay connected to each of them.

Seal records that convergence as one material and evidence lineage for AAV, lentiviral, adenoviral and other vector processes. Each programme configures its own science; no single vector, platform or expression system is assumed to fit all of them.

Why teams choose Seal for viral vector manufacturing

When plasmid manufacture, cell culture, purification and the analytical laboratory keep separate records, a plasmid finding or an invalid potency plate becomes a search across systems. Seal records the lineage from plasmid lot and bank vial through the transfection mixture and each pool to each assay result, and a process that is still maturing changes through versioned, approved updates rather than a revalidated system. A question about one of them is answered from the lineage, and release is evaluated against that lineage as its evidence matures.

1Start the batch from the vector design.

The controlled product connects vector type and serotype, expression cassette, genome sequence, plasmid set or producer construct, cell substrate, process, formulation, specifications, methods and regulatory state. Versions distinguish development, toxicology, clinical, PPQ and commercial material, and Seal prevents an outdated construct, plasmid ratio or process version from entering an active batch.

Plasmids are part of the vector batch. Each plasmid keeps its sequence version, bacterial bank, fermentation, purification, concentration, release and storage history, and helper, packaging, rep/cap and transgene plasmids keep their distinct roles. EU GMP for advanced therapies applies GMP principles to vectors and plasmids used as starting materials from the bank system that produces them.¹ At issue, Seal verifies the exact plasmid lot, status, concentration, freeze-thaw history and required ratio, so a later plasmid finding traces to every transfection and container it affected.

The cell substrate carries its own lineage. Master and working banks keep origin, passage history, characterisation, storage positions and withdrawals, and each thaw begins a traceable expansion. Adherent, suspension, transient-transfection and stable-producer processes use their own configured stages and acceptance gates while sharing the same genealogy principles.

2Treat transfection as a controlled transformation.

Seed expansion and production culture record vessels, passages, seeding density, viability, medium, holds, samples and acceptance decisions from thaw to production. The process controls permitted passage, timing, vessel and scale; aborted or partially harvested cultures stay visible in the lineage.

The transfection recipe defines plasmid roles and ratios, reagent, complexation volumes, order of addition, hold and the window from preparation to addition. Seal calculates target quantities from effective plasmid concentration and batch scale, then records actual masses, volumes, lots, timing and deviations. The transfection mixture becomes a named intermediate with its own hold and genealogy.

Processes using helper virus, infection, induction or stable production replace these stages with their own inputs, control parameters and acceptance logic. The record shows what actually occurred rather than forcing every batch into plasmid terminology.

3Keep quantities and vector state through harvest and purification.

Harvest, lysis, nuclease treatment, clarification, concentration and pooling are controlled transformations. Every source and destination container keeps its quantity, concentration, time, condition and samples. Many-to-one pools and one-to-many splits preserve contributions and yields, so a rejected fraction cannot disappear from the balance.

Columns, membranes, filters and single-use flow paths carry lot, qualification, cycle, integrity and product-contact history. Load, wash, elution, fractions, diafiltration, sterile filtration and formulation keep their parameters, samples, holds and decisions. Assemblies record component scans, sterilisation, integrity and connection events, so an unexpected open manipulation or filter-integrity failure carries its contamination impact into investigation and disposition.

Hold time, temperature and freeze-thaw are properties of the material. Defined events start clocks on plasmids, transfection complexes, harvests, pools and filled containers; scheduling sees approaching limits, and a freezer excursion identifies the exact containers and downstream material affected.

4Keep each assay attached to the question it answers.

Genome titre, capsid or particle titre, full-to-empty ratio, integrity, aggregation, residual DNA and protein, infectivity, expression and potency answer different questions. Each sample keeps its source culture or pool, method version, instrument, standard, dilution, raw data, calculation and decision. Total particles and functional activity are never collapsed into one generic “titre”.

Potency is a measurement system in its own right: cells, critical reagents, reference standards, controls, plate map, instrument data and suitability stay with each reportable result. Invalid runs, reference drift and method changes remain visible alongside manufacturing trends, because a batch cannot be interpreted without the method state that measured it.

Replication-competent virus, adventitious-agent, sterility, endotoxin and mycoplasma tests connect to the sample stage, method, laboratory and release requirement.² FDA’s CMC guidance for human gene therapy INDs addresses manufacturing, testing and controls; Seal organises the supporting evidence while sponsor science and regulatory strategy remain authoritative. Pending long-duration results stay visible, and any permitted conditional progression records its approved basis, population and follow-up.

5Evaluate release against the whole dependency graph.

Release draws on plasmid and bank status, culture and transfection, material and assembly genealogy, process data, pools, analytics, vector safety, equipment, holds, deviations, changes and container reconciliation. Fill, visual inspection, labels, freeze profile, frozen location and shipment continue the same lineage, with container counts reconciled at every stage.

The decision freezes the evidence available at approval. Later safety, stability, supplier or method findings attach to the historical lot and its distributed population. For ex vivo programmes, a vector lot can connect to the cell-therapy batches it transduces, preserving vector-to-patient impact without merging the two manufacturing records.

Changes to construct, plasmid source, cell bank, scale, transfection system, purification, method, site or container create explicit evidence cohorts. Development, clinical, PPQ and commercial data can be related without being treated as interchangeable, and comparability plans connect each difference to its studies, results and decisions.

6Prove one source-to-vial lineage.

Follow one vector lot from construct and plasmid set through bank vial, expansion, transfection, harvest, purification, formulation, fill, safety and potency testing, release, frozen storage and shipment. Include the cases that test the model: a plasmid concentration correction, a late transfection window, a failed filter integrity test, a lost historian interval, a full-to-empty result out of trend, an invalid potency plate, a pending replication-competent result, a freezer excursion and a post-release plasmid alert.

The model is ready when every vial traces back to both its biological and plasmid sources. Then extend it to further constructs, scales and sites on the same foundation.